scroll to top
0

EBSCO Auth Banner

Let's find your institution. Click here.

Advanced Search Results For "type 2 diabetes"

1 - 10 of 332,762 results for
 "type 2 diabetes"
Results per page:

Association of gene polymorphisms with body weight changes in prediabetic patients.

Publication Type: Academic Journal

Source(s): Molecular biology reports [Mol Biol Rep] 2022 Jun; Vol. 49 (6), pp. 4217-4224. Date of Electronic Publication: 2022 Mar 15.

Abstract: Background: Recent research has demonstrated that Type 2 Diabetes (T2D) risk is influenced by a number of common polymorphisms, including MC4R rs17782313, PPARG rs1801282, and TCF7L2 rs7903146. Knowledge of the association between these single nucleoti...

View details

Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: A perspective based on the updated evidence.

Publication Type: Academic Journal

Source(s): Diabetes, obesity & metabolism [Diabetes Obes Metab] 2022 Nov; Vol. 24 (11), pp. 2071-2080. Date of Electronic Publication: 2022 Aug 04.

Abstract: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are now seen as an integral part of therapy in type 2 diabetes to control not only blood glucose but to improve cardiovascular and kidney outcomes. Diabetic ketoacidosis (DKA) is an uncommon but serious...

View details

Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease.

Publication Type: Academic Journal

Source(s): Diabetes, obesity & metabolism [Diabetes Obes Metab] 2022 Nov; Vol. 24 (11), pp. 2138-2147. Date of Electronic Publication: 2022 Jul 06.

Abstract: Aims: To confirm the reno-protective effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with dipeptidyl peptidase-4 (DPP-4) inhibitors on the onset and progression of chronic kidney disease (CKD) in routine clinical practice.Material...

View details

SGLT2 Inhibitors in Type 2 Diabetes Mellitus.

Publication Type: Academic Journal

Source(s): Heart failure clinics [Heart Fail Clin] 2022 Oct; Vol. 18 (4), pp. 551-559.

Abstract: Sodium-glucose cotransporter 2 inhibitors were first discovered as glucose-lowering drugs because of their glycosuric action and good safety profile. Subsequently, they were studied in cardiovascular outcome trials in people with type 2 diabetes, and t...

View details

[Effect of electroacupuncture at "Tianshu" (ST25) on the regulation of nitrergic neurons in different intestinal segments in streptozotocin induced type 2 diabetic rats].

Publication Type: Academic Journal

Source(s): Zhen ci yan jiu = Acupuncture research [Zhen Ci Yan Jiu] 2022 Sep 25; Vol. 47 (9), pp. 785-92.

Authors:

Abstract: Objective: To observe the effect of electroacupuncture (EA) at "Tianshu" (ST25) on nitrergic neurons in jejunum and distal colon in type 2 diabetic rats, so as to explore its mechanism of regulating different intestinal segments.Methods: Twenty-four SD...

View details

Association of skin autofluorescence with low bone density/osteoporosis and osteoporotic fractures in type 2 diabetes mellitus.

Publication Type: Academic Journal

Source(s): Journal of diabetes [J Diabetes] 2022 Sep; Vol. 14 (9), pp. 571-585. Date of Electronic Publication: 2022 Sep 04.

Authors:

Abstract: Background: Advanced glycation end products (AGEs) that abnormally accumulate in diabetic patients have been reported to damage bone health. We aimed to investigate the association between skin autofluorescence (SAF)-AGE age (SAF - AGEs × age/100) and ...

View details

Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.

Publication Type: Academic Journal

Source(s): Diabetes, obesity & metabolism [Diabetes Obes Metab] 2022 Nov; Vol. 24 (11), pp. 2159-2168. Date of Electronic Publication: 2022 Jul 15.

Authors:

Abstract: Aims: To compare the efficacy of sodium-glucose cotransporter-2 (SGLT2) inhibitors, nonsteroidal mineralocorticoid receptor antagonists (MRAs), selective aldosterone antagonists and nonselective aldosterone antagonists, on top of renin-angiotensin-aldo...

View details

The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus.

Publication Type: Academic Journal

Source(s): Age and ageing [Age Ageing] 2022 Oct 06; Vol. 51 (10).

Abstract: Sodium-glucose co-transporter-2 (SGLT2) inhibitors offer significant outcome benefits beyond glucose lowering, including reduced risk of cardiovascular death, all-cause mortality, major adverse cardiovascular events, hospitalisations for heart failure ...

View details

Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial.

Publication Type: Academic Journal

Source(s): Diabetes, obesity & metabolism [Diabetes Obes Metab] 2022 Oct; Vol. 24 (10), pp. 1950-1956. Date of Electronic Publication: 2022 Jun 28.

Abstract: Aims: To test the hypothesis that the reduction in urinary kidney injury molecule-1 (KIM-1) observed with the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin is mediated through its effects on urine albumin to creatinine ratio (UACR) and...

View details

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure.

Publication Type: Academic Journal

Source(s): Cardiovascular diabetology [Cardiovasc Diabetol] 2022 Sep 23; Vol. 21 (1), pp. 194. Date of Electronic Publication: 2022 Sep 23.

Abstract: Background: Sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of kidney and heart failure events independent of glycemic effects. We assessed whether initiation of the SGLT2 inhibitor canagliflozin guided by multivariable predicted ris...

View details
sponsored